Prestige Biologics Co. Ltd.
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for… Read more
Market Cap & Net Worth: Prestige Biologics Co. Ltd. (334970)
Prestige Biologics Co. Ltd. (KQ:334970) has a market capitalization of $15.55K (₩22.77 Million) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22903 globally and #1200 in its home market, demonstrating a 2.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prestige Biologics Co. Ltd.'s stock price ₩2530.00 by its total outstanding shares 9001 (9.00K).
Prestige Biologics Co. Ltd. Market Cap History: 2021 to 2026
Prestige Biologics Co. Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $59.01K to $15.55K (-29.18% CAGR).
Index Memberships
Prestige Biologics Co. Ltd. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.02% | #580 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.02% | #580 of 1384 |
Weight: Prestige Biologics Co. Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Prestige Biologics Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prestige Biologics Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Prestige Biologics Co. Ltd.'s market cap is 0.00 times its annual revenue
0.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $59.01K | $3.23 Billion | -$39.38 Billion | 0.00x | N/A |
| 2022 | $18.57K | $15.57 Million | -$49.72 Billion | 0.00x | N/A |
| 2023 | $27.05K | $2.17 Billion | -$29.37 Billion | 0.00x | N/A |
| 2024 | $31.29K | $12.53 Billion | -$27.47 Billion | 0.00x | N/A |
Competitor Companies of 334970 by Market Capitalization
Companies near Prestige Biologics Co. Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to Prestige Biologics Co. Ltd. by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #3465 globally with a market cap of $3.69 Billion USD ( ₩5.41 Trillion KRW).
- Mezzion Pharma Co.Ltd (KQ:140410): Ranked #6393 globally with a market cap of $1.27 Billion USD ( ₩1.86 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #7113 globally with a market cap of $1.05 Billion USD ( ₩1.54 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #7795 globally with a market cap of $890.75 Million USD ( ₩1.30 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #3465 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $3.69 Billion | ₩739000.00 |
| #6393 | Mezzion Pharma Co.Ltd | KQ:140410 | $1.27 Billion | ₩89200.00 |
| #7113 | ST Pharm Co.Ltd | KQ:237690 | $1.05 Billion | ₩153400.00 |
| #7795 | Oscotec Inc | KQ:039200 | $890.75 Million | ₩54900.00 |
Prestige Biologics Co. Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Prestige Biologics Co. Ltd.'s market cap moved from $59.01K to $ 15.55K, with a yearly change of -29.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩15.55K | -16.64% |
| 2025 | ₩18.66K | -40.37% |
| 2024 | ₩31.29K | +15.68% |
| 2023 | ₩27.05K | +45.70% |
| 2022 | ₩18.57K | -68.54% |
| 2021 | ₩59.01K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Prestige Biologics Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.55K USD |
| MoneyControl | $15.55K USD |
| MarketWatch | $15.55K USD |
| marketcap.company | $15.55K USD |
| Reuters | $15.55K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.